A third of patients in a clinical trial had tumors shrink while taking a genetically engineered treatment known as RP1.
HealthWatch
FDA blocked melanoma drug as confusion reigned under Makary
By Arthur Allen
May 15, 2026 / 5:00 AM EDT / KFF Health News
Add CBS News on Google
A third of patients in a clinical trial had tumors shrink while taking a genetically engineered treatment known as RP1.
Replimune's RP1 faces tough test at upcoming FDA advisory panel meeting
Vote at odds with FDA reviewers
Replimune wins accelerated FDA approval for RP1 in advanced melanoma after two rejections, despite data concerns. Drug combines…
STAT is live-blogging a meeting of FDA experts to review Replimune’s experimental melanoma drug, RP1.
Replimune defends its single-arm RP1 melanoma trial data as an FDA advisory panel prepares to vote on whether results are…
